Speaking in the hallway at the 2017 Biotech Showcase, Marty Duvall revealed that Tocagen Inc. has developed a double-barreled approach that involves pairing Toca FC (extended-release 5-fluorocytosine), an inactive prodrug, with Toca 511 (vocimagene amiretrorepvec), a modified virus that infects the tumor and delivers an enzyme, which then activates the drug and allows it to kill the glioma cells.
Tocagen Aims Double Barrels At Glioma
Listen to this article
Emerging Company Profile: Gene therapy technology company Tocagen has glioma in its sights. Marty Duvall, newly appointed CEO of the San Diego-based firm, tells Mike Ward how his company’s approach has potential to double survival in one of the deadliest diseases, for which little to no effective treatments exist.
Keep up with the top pharma business news of the week. On the go.
More from Start-Ups & SMEs
- • By
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
- • By
The German group is spinning off from Eckert & Ziegler and listing in Frankfurt, though a leap to the NASDAQ will likely follow once it has more data on a lymphoma theranostic.
- • By
BridgeBio spun out oncology assets in May to focus on rare diseases and now it has sliced off a few rare disease candidates for GondolaBio. Also, Avidity and Kymera closed follow-on offerings that grossed $345.1m and $225m, respectively, and Vandria extended its series A round to $30.7m.
- • By
With $150m in series A funding, the Versant- and Novartis-backed start-up is betting it can overcome the challenges to getting RNA medicines into the kidney.
More from Business
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
